


Listing of Claims:

Claim 1. (original) A compound of the formula:



in which

R_1 is independently selected from the group consisting of hydrogen; hydroxy; halo; C_{1-8} alkyl; C_{1-8} alkoxy; substituted C_{1-8} alkyl wherein the substituent is halo; substituted C_{1-8} alkoxy wherein the substituent is halo; trifluoroalkyl; C_{1-8} alkylthio and substituted C_{1-8} alkylthio wherein the substituent is selected from halo, trifluoroalkyl and C_{1-8} alkoxy; C_{3-6} cycloalkyl; C_{3-8} cycloalkoxy; nitro; amino; C_{1-6} alkylamino; C_{1-8} dialkylamino; C_{4-8} cycloalkylamino; cyano; carboxy; C_{1-5} alkylcarbonyloxy; C_{1-5} alkoxycarbonyloxy; formyl; carbamoyl; phenyl; and substituted phenyl wherein the substituent is selected from halo, hydroxyl, nitro, amino and cyano;

n is 0-2;

B_2 is selected from the group consisting of hydrogen; C_{1-5} alkyl; substituted C_{1-5} alkyl wherein the substituent is halo;

B_2 may have either a *cis*- or *trans*- stereochemical orientation with respect to B_1 ;

Y is methylene (-CH₂-) or carbonyl (C=O)


L is selected from the group consisting of

C₁₋₈alkylene; C₂₋₁₀alkenylene; C₂₋₁₀alkynylene; C₃₋₇cycloalkylene;


C₃₋₇cycloalkylC₁₋₄alkylene;

arylC₁₋₄alkylene;

(N-methylene)piperidin-4-yl;




(N-methylene)piperazin-4-yl;



and

(N-methylene)piperidin-4,4-diyl;




R₂ is independently selected from the group consisting of hydrogen; C₁₋₅alkyl; substituted C₁₋₅alkyl wherein the substituent is halo;

B₁ is hydrogen;


B₁ may have either a *cis*- or *trans*- stereochemical orientation with respect to B₂;

Z is selected from the group consisting of:


phenyl;




N-sulfonamido;




N-(aryl)sulfonamido;



2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl;



and 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;



R_3 is selected from the group consisting of C_{1-8} alkyl; substituted C_{1-8} alkyl wherein the substituent is selected from alkoxy and halo; cycloalkyl; substituted cycloalkyl wherein the substituent is selected from C_{1-8} alkoxy and halo; naphthyl; substituted naphthyl wherein the substituent is

selected from halo, nitro, amino and cyano; heteroaryl wherein the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl and imidazolyl; and substituted heteroaryl wherein the substituent is selected from halo, nitro, amino and cyano;

R₄ is independently selected from the group consisting of C₁₋₈alkyl; alkoxy; hydroxy; halo; cyano, nitro; amino and alkylamino; substituted C₁₋₈alkyl wherein the substituent is halo;

m is 0-2;

with the following provisions:

when L is C₁₋₈alkylene; C₂₋₁₀alkenylene; C₂₋₁₀alkynylene; C₃₋₇cycloalkylene; C₃₋₇cycloalkyleneC₁₋₄alkylene; arylC₁₋₄alkylene; (N-methylene)piperidin-4-yl;

then Z is phenyl; N-sulfonamido; N-(aryl)sulfonamido; or 2,3-dihydro-2-oxo-1*H*-benzimidazol-1-yl;

when L is (N-methylene)piperazin-4-yl;
then Z is phenyl or aryl; and

when L is (N-methylene)piperidin-4,4,-diyl;
then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;

and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof.

Claim 2. (original) A compound of Claim 1 wherein R₁ is hydrogen, alkyl, halo, alkoxy, hydroxy, nitro, amino or trifluoroalkyl;

B₂ and B₁ are hydrogen;

R₂ is hydrogen or alkyl;

Y is methylene or carbonyl;

L is alkylene, alkenylene, alkynylene, (N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl or (N-methylene)piperidin-4,4-diyl;

Z is phenyl, N-sulfonamido, N(aryl)sulfonamido, 2,3-dihydro-2-oxo-1H-benzimidazo-1-yl or 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;

R₃ is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;

R₄ is alkyl, alkoxy, hydroxy, halo, cyano, nitro, amino, alkylamino or substituted alkyl;

n is 0-2;

m is 0-2;

provided that when:







L is C₁₋₈alkylene, C₂₋₁₀alkenylene; C₂₋₁₀alkynylene, C₃₋₇cycloalkylene, C₃₋₇cycloalkyleneC₁₋₄alkylene, arylC₁₋₄alkylene or (N-methylene)piperidin-4-yl, then Z is phenyl, N-sulfonamido, N-(aryl)sulfonamido or 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl;

when L is (N-methylene)piperazin-4-yl, then Z is phenyl; and

when L is (N-methylene)piperidin-4,4-diyl, then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;


and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

Claim 3. (original) A compound of claim 1 selected from the group consisting of:




and


Claim 4. (original) A compound of claim 1 selected from the group consisting of:




Claim 5. (original) A compound of claim 1 selected from the group consisting of:




Claim 6. (original) A compound of claim 1 selected from the group consisting of:









Claim 7. (original) A compound of claim 1 selected from the group consisting of:




Claim 8. (original) A compound of claim 1 selected from the group consisting of:




Claim 9. (original) A compound of claim 1 selected from the group consisting of:










Claim 10. (original) A compound of claim 1 selected from the group consisting of:









Claim 11. (original) A compound of claim 1 selected from the group consisting of:




Claim 12. (original) A compound of claim 1 selected from the group consisting of:




Claim 13. (original) A compound of claim 1 selected from the group consisting of:



Claim 14. (original) A compound of claim 1 selected from the group consisting of:



Claim 15. (withdrawn) A compound of the formula:



Wherein

R_1 is independently selected from the group consisting of hydrogen; hydroxy; halo; C_{1-8} alkyl; C_{1-8} alkoxy; substituted C_{1-8} alkoxy; trifluoroalkyl; C_{1-8} alkylthio; C_{3-6} cycloalkyl; C_{3-8} cycloalkyloxy; nitro; amino; C_{1-6} alkylamino; C_{1-8} dialkylamino; C_{4-8} cycloalkylamino; cyano; carboxy; C_{1-5} alkylcarbonyloxy; C_{1-5} alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl;


n is 0 to 2

R_3 is independently selected from the group consisting of C_{1-8} alkyl; substituted C_{1-8} alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl wherein the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl and imidazolyl; and substituted heteroaryl;

L is selected from the group consisting of C_{1-8} alkylene; C_{2-10} alkenylene; C_{2-10} alkynylene; C_{3-7} cycloalkylene; C_{3-7} cycloalkyl C_{1-4} alkylene; aryl C_{1-4} alkylene; (N- methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and (N-methylene)piperidin-4,4-diyl;

and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

Claim 16. (withdrawn) A compound of the formula:



R_1 is independently selected from the group consisting of hydrogen; hydroxy; halo; C_{1-8} alkyl; C_{1-8} alkoxy; substituted C_{1-8} alkoxy; trifluoroalkyl; C_{1-8} alkylthio; C_{3-6} cycloalkyl; C_{3-8} cycloalkyloxy; nitro; amino; C_{1-6} alkylamino; C_{1-8} dialkylamino; C_{4-8} cycloalkylamino; cyano; carboxy; C_{1-5} alkylcarbonyloxy; C_{1-5} alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl;


n is 0 to 2

R_4 is independently selected from the group consisting of C_{1-8} alkyl; alkoxy; hydroxy; halogen; cyano, nitro; amino and alkylamino; substituted C_{1-8} alkyl wherein the substituent is halo;

L is selected from the group consisting of
 C_{1-8} alkylene; C_{2-10} alkenylene; C_{2-10} alkynylene; C_{3-7} cycloalkylene;
 C_{3-7} cycloalkyl C_{1-4} alkylene; aryl C_{1-4} alkylene;
 (N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and
 (N-methylene)piperidin-4,4-diyl;

and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

Claim 17. (withdrawn) A compound of the formula:



Wherein

R₁ is independently selected from the group consisting of hydrogen; hydroxy; halo; C₁₋₈alkyl; C₁₋₈alkoxy; substituted C₁₋₈ alkoxy; trifluoroalkyl; C₁₋₈alkylthio; C₃₋₆cycloalkyl; C₃₋₈cycloalkyloxy; nitro; amino; C₁₋₆alkylamino; C₁₋₈dialkylamino; C₄₋₈cycloalkylamino; cyano; carboxy; C₁₋₅alkylcarbonyloxy; C₁₋₅alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl;

n is 0 to 2


HX is hydrochloric acid or trifluoroacetic acid

R₃ is independently selected from the group consisting of C₁₋₈alkyl; substituted C₁₋₈alkyl; cycloalkyl; substituted cycloalkyl; naphthyl; substituted naphthyl; heteroaryl wherein the heteroaryl group is selected from pyridyl, pyrimidyl, furyl, thienyl and imidazolyl; and substituted heteroaryl;

L is selected from the group consisting of
C₁₋₈alkylene; C₂₋₁₀alkenylene; C₂₋₁₀alkynylene; C₃₋₇cycloalkylene;
C₃₋₇cycloalkylC₁₋₄alkylene; arylC₁₋₄alkylene;
(N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and
(N-methylene)piperidin-4,4-diyl;

and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

Claim 18. (withdrawn) A compound of the formula:



wherein

R₁ is independently selected from the group consisting of hydrogen; hydroxy; halo; C₁₋₈alkyl; C₁₋₈alkoxy; substituted C₁₋₈ alkoxy; trifluoroalkyl; C₁₋₈alkylthio; C₃₋₆cycloalkyl; C₃₋₈cycloalkyloxy; nitro; amino; C₁₋₆alkylamino; C₁₋₈dialkylamino; C₄₋₈cycloalkylamino; cyano; carboxy; C₁₋₅alkylcarbonyloxy; C₁₋₅alkoxycarbonyloxy; formyl; carbamoyl; phenyl and substituted phenyl;

HX is hydrochloric acid or trifluoroacetic acid

n is 0 to 2

R₄ is independently selected from the group consisting of C₁₋₈alkyl; alkoxy; hydroxy; halogen; cyano, nitro; amino and alkylamino; substituted C₁₋₈alkyl wherein the substituent is halo;

L is selected from the group consisting of
C₁₋₈alkylene; C₂₋₁₀alkenylene; C₂₋₁₀alkynylene; C₃₋₇cycloalkylene;
C₃₋₇cycloalkylC₁₋₄alkylene; arylC₁₋₄alkylene;
(N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and
(N-methylene)piperidin-4,4-diyl;

and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

Claim 19. (currently amended) A compound of Claim 15 wherein:

R₁ is hydrogen, alkyl, halo, alkoxy, hydroxy, nitro, amino or trifluoroalkyl;

B₂ and B₁ are hydrogen;

R₂ is hydrogen or alkyl;

Y is methylene or carbonyl;

L is selected from the group consisting of
C₁₋₈alkylene; C₂₋₁₀alkenylene; C₂₋₁₀alkynylene; C₃₋₇cycloalkylene;
C₃₋₇cycloalkylC₁₋₄alkylene; arylC₁₋₄alkylene;
(N-methylene)piperidin-4-yl, (N-methylene)piperazin-4-yl and
(N-methylene)piperidin-4,4-diyl;

Z is phenyl, N-sulfonamido, N(aryl)sulfonamido, 2,3-dihydro-2-oxo-1H-benzimidazo-1-yl or 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;

R₃ is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl;

R₄ is independently selected from the group consisting of C₁₋₈alkyl; alkoxy; hydroxy; halogen; cyano, nitro; amino; alkylamino; and substituted C₁₋₈alkyl wherein the substituent is halo;

n is 0-2;

m is 0-2;

provided that when:

L is C₁₋₈alkylene, C₂₋₁₀alkenylene; C₂₋₁₀alkynylene, C₃₋₇cycloalkylene, C₃₋₇cycloalkyleneC₁₋₄alkylene, arylC₁₋₄alkylene or (N-methylene)piperidin-4-yl, then Z is phenyl, N-sulfonamido, N-(aryl)sulfonamido or 2,3-dihydro-2-oxo-1H-benzimidazol-1-yl;

when L is (N-methylene)piperazin-4-yl, then Z is phenyl; and when

L is (N-methylene)piperidin-4,4-diyl, then Z is 1-aryl-2,3-dihydro-4-oxo-imidazol-5,5-diyl;

and the enantiomers, diastereomers and pharmaceutically acceptable salts thereof.

Claim 20. (previously amended) A method of treating disorders and diseases associated with NPY receptor subtype Y5 comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 selected from the group consisting of eating disorders, obesity, anorexia nervosa, bulimia nervosa, diabetes, dyslipidemia, hypertension, memory loss, epileptic seizures, migraine, sleep disorders, pain, sexual/reproductive disorders, depression and anxiety.

Claim 21. (canceled)

Claim 22. (previously amended) A pharmaceutical composition according to Claim 20 for the treatment of disorders or disease states caused by eating disorders, obesity, anorexia nervosa, bulimia nervosa, diabetes, dyslipidemia, hypertension, memory loss, epileptic seizures, migraine, sleep disorders, pain, sexual/reproductive disorders, depression or anxiety.